Tags

Type your tag names separated by a space and hit enter

Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals.
Talanta. 2008 Jan 15; 74(4):694-8.T

Abstract

A simple and rapid capillary zone electrophoresis (CZE) method with UV detection has been developed for the determination of famotidine and its potential impurities in pharmaceutical formulations. The electrophoretic separation of these compounds was performed using a fused silica capillary and 37.5mmolL(-1) phosphate buffer pH 3.5 as the electrolyte. Under the optimised conditions, six impurities could be resolved from the famotidine peak in less than 7min. The calibration curves obtained for the seven compounds were linear over the concentration range investigated (from 1.5 to 78.5microg mL(-1)). The intra- and inter-day relative standard deviations for the migration times and corrected peak areas were less than 2% and 5%, respectively. The detection limits were found to be 0.09microg mL(-1) for famotidine, and from 0.1 to 0.62microg mL(-1) depending on the impurities. The method has been successfully applied to the determination of famotidine in commercial dosage forms.

Authors+Show Affiliations

Institut National des Sciences Appliquées et de Technologie, Laboratoire de Chimie Analytique et Electrochimie 04UR12-01, Centre Urbain Nord, B.P. No. 676, 1080 Tunis Cedex, Tunisia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18371695

Citation

Helali, N, et al. "Capillary Zone Electrophoresis Method for the Determination of Famotidine and Related Impurities in Pharmaceuticals." Talanta, vol. 74, no. 4, 2008, pp. 694-8.
Helali N, Tran NT, Monser L, et al. Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals. Talanta. 2008;74(4):694-8.
Helali, N., Tran, N. T., Monser, L., & Taverna, M. (2008). Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals. Talanta, 74(4), 694-8. https://doi.org/10.1016/j.talanta.2007.06.036
Helali N, et al. Capillary Zone Electrophoresis Method for the Determination of Famotidine and Related Impurities in Pharmaceuticals. Talanta. 2008 Jan 15;74(4):694-8. PubMed PMID: 18371695.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals. AU - Helali,N, AU - Tran,N T, AU - Monser,L, AU - Taverna,M, Y1 - 2007/07/01/ PY - 2007/04/21/received PY - 2007/06/25/revised PY - 2007/06/27/accepted PY - 2008/3/29/pubmed PY - 2008/8/30/medline PY - 2008/3/29/entrez SP - 694 EP - 8 JF - Talanta JO - Talanta VL - 74 IS - 4 N2 - A simple and rapid capillary zone electrophoresis (CZE) method with UV detection has been developed for the determination of famotidine and its potential impurities in pharmaceutical formulations. The electrophoretic separation of these compounds was performed using a fused silica capillary and 37.5mmolL(-1) phosphate buffer pH 3.5 as the electrolyte. Under the optimised conditions, six impurities could be resolved from the famotidine peak in less than 7min. The calibration curves obtained for the seven compounds were linear over the concentration range investigated (from 1.5 to 78.5microg mL(-1)). The intra- and inter-day relative standard deviations for the migration times and corrected peak areas were less than 2% and 5%, respectively. The detection limits were found to be 0.09microg mL(-1) for famotidine, and from 0.1 to 0.62microg mL(-1) depending on the impurities. The method has been successfully applied to the determination of famotidine in commercial dosage forms. SN - 1873-3573 UR - https://www.unboundmedicine.com/medline/citation/18371695/Capillary_zone_electrophoresis_method_for_the_determination_of_famotidine_and_related_impurities_in_pharmaceuticals_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039-9140(07)00473-0 DB - PRIME DP - Unbound Medicine ER -